RESEARCH USE ONLY. Reference data for laboratory research. Not medical advice; not for human consumption.
Peptijournal
Calc
← Directory

Protocol Single compound

ARA-290

Cibinetide

Erythropoietin-derived peptide referenced in innate repair receptor research.

Compare side by side →
Tissue Repair

Laboratory reference · in vitro research data

Research vial sizes
10 mg
Dosing data
Not listed — reference entry covers vial concentration only.
Storage
Powder: 2–8 °C, or −20 °C for longer storage. After mixing with BAC water: 2–8 °C, use within about 4 weeks.

Reconstitution concentrations

Concentration per BAC-water volume; 10 units = 0.1 mL on a U-100 syringe.

VialBAC watermg/mLmg per 10 u
10 mg1 mL101
10 mg2 mL50.5
10 mg3 mL3.330.333

Calculate your vial

Add reminder

Enter your own schedule. Saved only on this device — never sent anywhere.

Research use only — educational reference, not medical advice. This line is added to every reminder.

Works with iPhone Calendar, Google Calendar and Outlook.

Saved only in this browser. My reminders

Inputs
mg
mL
1 mg = 1,000 mcg
mg

Draw to

—units

= — mL on a U-100 syringe

Concentration
—
Per unit
—
Doses / vial
—
Syringe
01020304050607080901000.0u
U-100 · 100 units (1 mL)2 unit per line

Research dossier · published literature summary

01

Mechanism of action

ARA-290 (cibinetide) is an 11-amino-acid peptide derived from erythropoietin that activates the innate repair receptor without stimulating red-blood-cell production. It is studied for small-nerve-fibre damage and neuropathic pain.

02

Observed research endpoints

  • Sarcoidosis small-fibre neuropathy RCT: corneal nerve fibre area rose significantly at day 28 in one arm, skin nerve fibres increased, and pain improved in all groups.
  • Type 2 diabetes neuropathy RCT: neuropathic symptoms (PainDetect) improved and HbA1c and lipid profiles improved over 56 days.

03

Regulatory & safety context

  • Not approved by the FDA or EMA for any indication; research-grade material is not a medicine.
  • No potential safety issues were identified in the type 2 diabetes trial; trials were small and short.

04

Citations

  1. Culver DA, et al. Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain. Invest Ophthalmol Vis Sci. 2017;58(6):BIO52–BIO60.2017Phase 2 randomized controlled trialRead paper ↗
  2. Brines M, et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol Med. 2015;20:658–666.2015-03Phase 2 randomized controlled trialRead paper ↗

Keep exploring

Where researchers source it

Listings are provided for reference — always verify the latest third-party COA before purchasing.

Medvinci Research

See site

Featured supplier · third-party tested, COA published per batch

View product View COA

Supplier B

TBD

Placeholder — details coming soon

View productView COA

Supplier C

TBD

Placeholder — details coming soon

View productView COA